Clinical Trial Update: A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update indicates that Nemtabrutinib (MK-1026) is being studied for relapsed or refractory hematologic malignancies in a Phase 1/2 trial, wit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Mantle Cell Lymphoma
• Marginal Zone Lymphoma
• Richter Transformation
• Small Lymphocytic Lymphoma
• Waldenström Macroglobulinemia

Drugs mentioned

• Nemtabrutinib (nemtabrutinib)

Snippet

Sponsor: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | Conditions: Lymphoma, B-Cell, Small Lymphocytic Lymphoma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING